Published online 22 June 2009
Haematologica, Vol 94, Issue 8, 1151-1156 doi:10.3324/haematol.2008.001735
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wehner, R.
Right arrow Articles by Schmitz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wehner, R.
Right arrow Articles by Schmitz, M.

Hematopoietic Stem Cells

Mesenchymal stem cells efficiently inhibit the proinflammatory properties of 6-sulfo LacNAc dendritic cells

Rebekka Wehner1, Diana Wehrum1, Martin Bornhäuser2,3, Senming Zhao1, Knut Schäkel1,3, Michael P. Bachmann1,3, Uwe Platzbecker2, Gerhard Ehninger2,3, E. Peter Rieber1,3, Marc Schmitz1,3

1 Institute of Immunology, Medical Faculty, Technical University, Dresden;
2 Department of Medicine I, Medical Faculty, Technical University, Dresden, Germany and
3 Center for Regenerative Therapies Dresden, Dresden, Germany

Correspondence: Marc Schmitz, M.D., Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstr. 74, 01307 Dresden, Germany. E-mail:marc.schmitz{at}tu-dresden.de

Mesenchymal stem cells emerged as a promising treatment modality for steroid-refractory graft-versus-host disease, which represents a major complication of allogeneic hematopoietic stem cell transplantation. Dendritic cells (DCs) display an extraordinary capacity to induce T-cell responses and play a crucial role in the pathogenesis of graft-versus-host disease. Here, we investigated the impact of mesenchymal stem cells on the proinflammatory capacity of 6-sulfo LacNAc (slan) dendritic cells, representing a major subpopulation of human blood dendritic cells. Mesenchymal stem cells markedly impair maturation of slanDCs and their ability to secrete proinflammatory cytokines, which was dependent on prostaglandin E2. In contrast, the release of anti-inflammatory IL-10 was improved by mesenchymal stem cells. Furthermore, mesenchymal stem cells efficiently inhibit slanDC-induced proliferation of CD4+ and CD8+ T cells and polarization of naïve CD4+ T lymphocytes into Th1 cells. These results indicate that mesenchymal stem cells significantly impair the high proinflammatory capacity of slanDCs and further substantiate their potential for the treatment of graft-versus-host disease.

Key words: dendritic cells, mesenchymal stem cells, T cells, graft-versus-host disease.